341 related articles for article (PubMed ID: 33230644)
1. Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper.
Cooksley T; Font C; Scotte F; Escalante C; Johnson L; Anderson R; Rapoport B
Support Care Cancer; 2021 Feb; 29(2):1129-1138. PubMed ID: 33230644
[TBL] [Abstract][Full Text] [Related]
2. Older patients with cancer and febrile neutropenia in the COVID-19 era: A new concern.
Tralongo AC; Extermann M
J Geriatr Oncol; 2020 Nov; 11(8):1329-1330. PubMed ID: 32571666
[No Abstract] [Full Text] [Related]
3. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
Ahn S; Rice TW; Yeung SJ; Cooksley T
Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
[TBL] [Abstract][Full Text] [Related]
4. [Prevention and treatment of febrile neutropenia].
Montemurro F; Gallicchio M; Aglietta M
Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
[TBL] [Abstract][Full Text] [Related]
5. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
6. Managing low-risk febrile neutropenia in children in the time of COVID-19: What matters to parents and clinicians.
Haeusler GM; De Abreu Lourenco R; Bakos C; O'Brien T; Slavin MA; Clark JE; McMullan B; Borland ML; Babl FE; Krishnasamy M; Vanevski M; Thursky KA; Hall L
J Paediatr Child Health; 2021 Jun; 57(6):826-834. PubMed ID: 33533525
[TBL] [Abstract][Full Text] [Related]
7. Is It Safe to Use Long-Acting G-CSF for Febrile Neutropenia Prophylaxis in COVID-19 Pandemic?
Ergun Y; Esen SA; Ucar G; Acikgoz Y; Karacin C
JCO Oncol Pract; 2021 Jul; 17(7):455-456. PubMed ID: 33797950
[No Abstract] [Full Text] [Related]
8. Can Risk Stratification Tools Be Utilized to Safely Discharge Low-Risk Febrile Neutropenic Patients from the Emergency Department?
Chen AY; Gottlieb M; Vilke GM; Coyne C
J Emerg Med; 2023 Jan; 64(1):111-118. PubMed ID: 36641256
[TBL] [Abstract][Full Text] [Related]
9. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
10. Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia.
Gunderson CC; Erickson BK; Wilkinson-Ryan I; Vesely SK; Leath CA; Gehrig PA; Moore KN
Am J Clin Oncol; 2019 Feb; 42(2):138-142. PubMed ID: 30557164
[TBL] [Abstract][Full Text] [Related]
11. Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center.
Nguyen M; Jacobson T; Torres J; Wann A
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1345. PubMed ID: 33635593
[TBL] [Abstract][Full Text] [Related]
12. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M
Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692
[TBL] [Abstract][Full Text] [Related]
13. Emerging cancer therapies and granulocyte-colony stimulating factor in febrile neutropenia patients presenting to the emergency department during the COVID-19 pandemic era.
Lai WJ; Hsu CX
Am J Emerg Med; 2023 Jun; 68():189-190. PubMed ID: 37088670
[No Abstract] [Full Text] [Related]
14. Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study.
van Marcke C; Honoré N; van der Elst A; Beyaert S; Derouane F; Dumont C; Aboubakar Nana F; Baurain JF; Borbath I; Collard P; Cornélis F; De Cuyper A; Duhoux FP; Filleul B; Galot R; Gizzi M; Mazzeo F; Pieters T; Seront E; Sinapi I; Van den Eynde M; Whenham N; Yombi JC; Scohy A; van Maanen A; Machiels JP
BMC Cancer; 2021 May; 21(1):578. PubMed ID: 34016086
[TBL] [Abstract][Full Text] [Related]
15. Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review.
Pherwani N; Ghayad JM; Holle LM; Karpiuk EL
Am J Health Syst Pharm; 2015 Apr; 72(8):619-31. PubMed ID: 25825185
[TBL] [Abstract][Full Text] [Related]
16. Emergency Ambulatory Management of Low-Risk Febrile Neutropenia: Multinational Association for Supportive Care in Cancer Fits-Real-World Experience From a UK Cancer Center.
Marshall W; Campbell G; Knight T; Al-Sayed T; Cooksley T
J Emerg Med; 2020 Mar; 58(3):444-448. PubMed ID: 31744709
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
[TBL] [Abstract][Full Text] [Related]
18. Usefulness analysis of the 2018 ASCO/IDSA guideline for outpatient management of fever and neutropenia in adults treated for malignancy.
Hwang S; Kwon KT; Kim Y; Bae S; Chang HH; Kim SW; Yoo SS; Nam SY; Baek JH
Sci Rep; 2021 Sep; 11(1):9048. PubMed ID: 34526516
[TBL] [Abstract][Full Text] [Related]
19. Risk assessment of febrile neutropenia and evaluation of G-CSF use in patients with cancer: a real-life study.
Aras E; Bayraktar-Ekincioglu A; Kilickap S
Support Care Cancer; 2020 Feb; 28(2):691-699. PubMed ID: 31127438
[TBL] [Abstract][Full Text] [Related]
20. Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC).
Rapoport BL; Cooksley T; Johnson DB; Anderson R; Shannon VR
Expert Rev Clin Pharmacol; 2021 Mar; 14(3):295-313. PubMed ID: 33517803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
